UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Emerging growth company ☒ If an emerging ...

Fulcrum | --- | --- | --- | --- | --- | |---------------------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | Regulating Gene Expression to Treat the Root Cause of Disease March 2021 | | | | | | | | | | | Disclaimer and Notice This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the dev ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2020 Results Earnings Conference Call March 4, 2021 8:00 AM ET Company Participants Christi Waarich - Director, Investor Relations and Corporate Communications Robert Gould - President & CEO Bryan Stuart - Chief Operating Officer Chris Moxham - Chief Scientific Officer Peter Thomson - Vice President, Finance and Accounting Conference Call Participants Ted Tenthoff - Piper Sandler Joseph Schwartz - SVB Leerink Dae Gon Ha - Stifel Matthew Harrison - Morgan Stanley O ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38978 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its Charter) Delaware 47-4839948 (State or other jurisdict ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2020 Earnings Conference Call November 9, 2020 8:00 AM ET Company Participants Robert Gould - CEO, President & Director Diego Cadavid - SVP of Clinical Development Owen Wallace - Chief Scientific Officer Bryan Stuart - Chief Operating Officer Christi Waarich - Director, Corporate Communications & IR Conference Call Participants Ted Tenthoff - Piper Sandler Joseph Schwartz - SVB Leerink Kostas Biliouris - Morgan Stanley Operator Good morning, and welcome to the Ful ...

For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4839948 (State or other j ...

Fulcrum | --- | --- | --- | --- | |-------------------------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | Regulating Gene Expression to Treat the Root Cause of Disease September 2020 | | | | | | | | | Disclaimer and Notice This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the development statu ...

Fulcrum | --- | --- | --- | --- | --- | --- | |---------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Fulcrum Q2 2020 Conference Call | | | | | | | August 11, 2020 | | | | | | | | | | | | | | | | | | | | Disclaimer and Notice This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regard ...

Fulcrum Therapeutics Inc. (NASDAQ:FULC) Q2 2020 Results Conference Call August 11, 2020 8:00 AM ET Company Participants Christi Waarich - Director, Corporate Communications & IR Robert Gould - CEO, President & Director Diego Cadavid - SVP of Clinical Development Owen Wallace - Chief Scientific Officer Bryan Stuart - Chief Operating Officer Conference Call Participants Joseph Schwartz - SVB Leerink Dae Gon Ha - BTIG Tazeen Ahmad - Bank of America Ted Tenthoff - Piper Sandler Matthew Harrison - Morgan Stanl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4839948 (State or other jurisd ...